LMNA and Hutchinson-Gilford progeria syndrome: To investigate whether all affected tissues should be targeted to ameliorate disease symptoms, or whether tissue-specific therapies would be effective, we examined the effect of suppressing progerin and restoring lamin A only in VSMCs and cardiomyocytes, major progerin targets in patients with HGPS and animal models.2,6,7,14,20–28 For this analysis, we used the SM22α-Cre transgenic line—which allows Cre-dependent recombination in VSMCs and cardiomyocytes31—to generate HGPSrev-SM22α-Cre mice.